OBIO CAAP Company: Intronix Technologies Launches Myoguide DOC

Ontario Industry Updates
Written By obio

OBIO CAAP 2014 company, Intronix Technologies, will be launching "Myoguide DOC", a comprehensive software package designed to help clinicians who inject Botulinum Toxins, such as Botox®, Dysport® and Xeomin® to manage their patient's spasticity and pain.

Click HERE to read the full press release. 

obio
Previous

MaRS Innovation and KHIDI Commence Joint Research Initiatives
Next

Steadiwear Wins Again!